Code | CSB-RA218051A0HU |
Size | US$210 |
Order now | |
Image |
|
Have Questions? | Leave a Message or Start an on-line Chat |
Application | Recommended Dilution |
---|---|
IHC | 1:50-1:200 |
The EZH2 recombinant monoclonal antibody is produced using a combination of protein technology and DNA recombinant technology. Initially, mice were injected with a synthesized peptide that was derived from human EZH2 to stimulate the production of antibodies. After a specific period of time, the spleen was extracted from the mice under sterile conditions, and the cDNA synthesized from RNA reverse transcription was utilized as a template to amplify the EZH2 antibody gene by PCR. The amplified EZH2 antibody gene was then inserted into a vector, which was transfected into host cells for cultivation. The EZH2 recombinant monoclonal antibody is purified from the cell culture supernatant via affinity chromatography. It underwent stringent testing and has been validated for use in ELISA and IHC experiments to detect human EZH2 protein.
The EZH2 protein is the catalytic subunit of the Polycomb repressive complex 2 (PRC2) and is involved in gene silencing through histone modification. EZH2 functions as a histone methyltransferase that specifically methylates H3K27 using S-adenosylmethionine (SAM) as a cofactor, resulting in transcriptional repression of target genes. The H3K27me3 mark generated by EZH2 is recognized by other PRC2 components, leading to further chromatin compaction and inhibition of transcriptional activity. Dysregulation of EZH2 has been implicated in the development and progression of various cancers.
There are currently no reviews for this product.